Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 2/2010

01-02-2010 | For Debate

Mitogenic action of insulin: friend, foe or ‘frenemy’?

Author: B. Draznin

Published in: Diabetologia | Issue 2/2010

Login to get access

Abstract

Either endogenous or exogenous hyperinsulinaemia in the setting of insulin resistance promotes phosphorylation and activation of farnesyltransferase, a ubiquitous enzyme that farnesylates Ras proteins. Increased availability of farnesylated Ras at the plasma membrane enhances mitogenic responsiveness of cells to various growth factors, thus contributing to progression of cancer and atherosclerosis. This effect is specific to insulin, but is not related to the type of insulin used. The stimulatory effect of hyperinsulinaemia on farnesyltransferase in the presence of insulin resistance represents one potential mechanism responsible for mitogenicity and atherogenicity of insulin.
Literature
1.
Muntoni S, Muntoni S, Draznin B (2008) Effects of chronic hyperinsulinemia in insulin-resistant patients. Current Diabetes Reports 8:233–238CrossRefPubMed
2.
Gupta K, Krishnaswamy G, Karnad A, Peiris AN (2002) Insulin: a novel factor in cancerogenesis. Am J Med Sci 323:140–145CrossRefPubMed
3.
Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732–1744CrossRefPubMed
4.
Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S (2007) Steineck G (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 50:1418–1422CrossRef
5.
Currie CJ, Poole CD (2009) Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777CrossRefPubMed
6.
Smith U (2009) Gale EAM (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699–1708CrossRefPubMed
7.
Sasaoka T, Rose DW, Jhun BH, Saltiel AR, Draznin B, Olefsky JM (1994) Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem 269:13689–13694PubMed
8.
Ish-Shalom D, Christoffersen CT, Vorwerk P et al (1977) Mitogenic properties of insulin and insulin analogs mediated by the insulin receptor. Diabetologia 40:525–531
9.
Goalstone ML, Leitner JW, Wall K et al (1998) Insulin’s effect on farnesyltransferase: specificity of insulin action and potentiation of nuclear effects of IGF-1, EGF, and PDGF. J Biol Chem 273:23892–23896CrossRefPubMed
10.
Draznin B, Miles P, Kruszynska Y et al (2000) Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia. Endocrinology 141:1310–1316CrossRefPubMed
11.
Medema SL, deVries-Smits AMM, van der Zon GCM, Maasen JA, Bos JL (1993) Ras activation by insulin and epidermal growth factor through enhanced exchange of guanine nucleotides on p21Ras. Mol Cell Biol 13:153–162
12.
Zhang FL, Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241–269CrossRefPubMed
13.
Goalstone ML, Draznin B (1996) Effect of insulin on farnesyltransferase activity in 3T3-L1 adipocytes. J Biol Chem 271:27585–27589CrossRefPubMed
14.
Goalstone ML, Carel K, Leitner JW, Draznin B (1997) Insulin stimulates the phosphorylation and activity of farnesyltransferase via the Ras-Map kinase pathway. Endocrinology 138:5119–5124CrossRefPubMed
15.
Leitner JW, Kline T, Carel K, Goalstone ML, Draznin B (1997) Hyperinsulinemia potentiates activation of p21Ras by growth factors. Endocrinology 138:2211–2214CrossRefPubMed
16.
Finlayson C, Chappell J, Leitner JW et al (2003) Enhanced insulin signaling via Shc in human breast cancer. Metabolism 52:1606–1608CrossRefPubMed
17.
Wang CCL, Goalstone ML, Draznin B (2004) Molecular mechanisms of insulin resistance that impact on cardiovascular biology. Diabetes 53:2735–2740CrossRefPubMed
18.
Goalstone ML, Wall K, Leitner JW et al (1999) Increased amounts of farnesylated p21 Ras in tissues of hyperinsulinemic animals. Diabetologia 42:310–316CrossRefPubMed
19.
Stephens E, Thureen PJ, Goalstone ML et al (2001) Fetal hyperinsulinemia increases farnesylation of p21 Ras in fetal tissues. Am J Physiol 281:E217–E223
20.
Montagnani M, Golovchenko I, Kim I et al (2002) Inhibition of phosphatidylinositol 3-kinase enhances mitogenic action of insulin in endothelial cells. J Biol Chem 277:1794–1799CrossRefPubMed
21.
Thureen P, Reece M, Donna D et al (2006) Increased farnesylation of p21-Ras and neonatal macrosomia in women with gestational diabetes. J Pediatrics 149:871–873CrossRef
22.
23.
Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258CrossRefPubMed
24.
Jiralerspong S, Palla SL, Giordano SH et al (2009) Metformin and pathologic complete response to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302CrossRefPubMed
Metadata
Title
Mitogenic action of insulin: friend, foe or ‘frenemy’?
Author
B. Draznin
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1558-6

Other articles of this Issue 2/2010

Diabetologia 2/2010 Go to the issue

Letter

The economic costs of diabetes in Iran: some concerns and recommendations. Reply to Khuwaja AK, Khowaja LA, Cosgrove P [letter]

Short Communication

A case of recurrent type 1 diabetes mellitus with insulitis of transplanted pancreas in simultaneous pancreas–kidney transplantation from cardiac death donor

Erratum

Erratum to: Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

Article

Common variants at the GCK, GCKR, G6PC2–ABCB11 and MTNR1B loci are associated with fasting glucose in two Asian populations

Erratum

Erratum to: Neural crest stem cells increase beta cell proliferation and improve islet function in co-transplanted murine pancreatic islets

Short Communication

Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits